ELOVL1
Elongation of very long chain fatty acids protein 1
Protein Summary
Catalyzes the first and rate-limiting reaction of the four that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process, allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids/VLCFAs per cycle. Condensing enzyme that exhibits activity toward saturated C18 to C26 acyl-CoA substrates, with the highest activity towards C22:0 acyl-CoA. May participate in the production of both saturated and monounsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. Important for saturated C24:0 and monounsaturated C24:1 sphingolipid synthesis. Indirectly inhibits RPE65 via production of VLCFAs.
- ENST00000372458
- ENSP00000361536
- ENSG00000066322
- ENST00000413844
- ENSP00000416024
- ENST00000621943
- ENSP00000477602
- SSC1
- Ssc1
- CGI-88
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
transcription factor perturbation | 1 | ||
disease perturbation | 0.95 | ||
transcription factor binding site profile | 0.69 | ||
histone modification site profile | 0.67 | ||
transcription factor | 0.65 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 34.73 (req: < 5)
Gene RIFs: 5 (req: <= 3)
Antibodies: 197 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 34.73 (req: >= 5)
Gene RIFs: 5 (req: > 3)
Antibodies: 197 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 14
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0
Expression Data (0 Tissues)
Protein Sequence and Structure
Residue Counts
Protein Sequence
ProtVista Viewer
Related Tools (4)
TIGA scores and ranks GWAS discovered associations according to the quantity and quality of the evidence supporting the association.
GENEVA (GENe Expression Variance Analysis) allows you to identify RNA-sequencing datasets from the Gene Expression Omnibus (GEO) that contain conditions modulating a gene or a gene signature.
GlyGen is a data integration and dissemination project for carbohydrate and glycoconjugate related data.
ARCHS4 provides access to gene-function predictions based on RNA-seq co-expression, and gene expression levels across cell and tissues.
Approved Drugs (0)
Active Ligands (0)
Protein-Protein Interactions (56)
Nearest Tclin Targets
Pathways (14)
Reactome (8)
KEGG (4)
PathwayCommons (1)
UniProt (1)
Click on a row in the table to change the structure displayed.
Data Source | Name | Explore in Pharos | Explore in Source | ||
|---|---|---|---|---|---|
Reactome | Fatty acid metabolism | ||||
Reactome | Fatty acyl-CoA biosynthesis | ||||
Reactome | Linoleic acid (LA) metabolism | ||||
Reactome | Metabolism | ||||
Reactome | Metabolism of lipids | ||||
Name | Explore in Pharos | Explore in Source | ||
|---|---|---|---|---|
Fatty acid metabolism | ||||
Fatty acyl-CoA biosynthesis | ||||
Linoleic acid (LA) metabolism | ||||
Metabolism | ||||
Metabolism of lipids | ||||
Viral Interactions (0)
Gene Ontology Terms (18)
Functions (5)
Components (4)
Processes (9)
GO Term | Evidence | Assigned by | ||
|---|---|---|---|---|
Inferred from Direct Assay (IDA) | UniProtKB | |||
Inferred from Electronic Annotation (IEA) | UniProtKB-EC | |||
Inferred from Electronic Annotation (IEA) | UniProtKB-EC | |||
Inferred from Electronic Annotation (IEA) | UniProtKB-EC | |||
Inferred from Electronic Annotation (IEA) | UniProtKB-EC | |||
Disease Associations (null)
GWAS Traits (11)
Items per page:
1 – 5 of 11
GWAS Trait | EFO ID | Study Count | SNP Count | Beta Count | Odds Ratio | Evidence (Mean Rank Score) | Provenance | ||
|---|---|---|---|---|---|---|---|---|---|
platelet count | 2 | 4 | 4 | 92.3 | |||||
platelet crit | 2 | 3 | 4 | 88.5 | |||||
systolic blood pressure | 1 | 1 | 1 | 71.9 | |||||
cognitive function measurement | 1 | 1 | 1 | 47.7 | |||||
asparaginase-induced acute pancreatitis | 1 | 1 | 0 | 4.6 | 30.2 | ||||
Items per page:
1 – 5 of 11
GWAS Trait | EFO ID | Beta Count | Odds Ratio | Evidence (Mean Rank Score) | Provenance | ||
|---|---|---|---|---|---|---|---|
platelet count | 4 | 92.3 | |||||
platelet crit | 4 | 88.5 | |||||
systolic blood pressure | 1 | 71.9 | |||||
cognitive function measurement | 1 | 47.7 | |||||
asparaginase-induced acute pancreatitis | 0 | 4.6 | 30.2 | ||||
Find similar targets by:
IDG Resources
Orthologs (13)
1 – 5 of 13
Species | Name | Source ID | Gene ID | OMA | EggNOG | Inparanoid | ||
|---|---|---|---|---|---|---|---|---|
Chimp | ELOVL fatty acid elongase 1 | VGNC:529 | 456820 | |||||
Macaque | ELOVL fatty acid elongase 1 | 700557 | ||||||
Mouse | MGI:1858959 | 54325 | ||||||
Rat | RGD:1587151 | 679532 | ||||||
Dog | ELOVL fatty acid elongase 1 | VGNC:40319 | 100855761 | |||||
Species | Name | OMA | EggNOG | Inparanoid | ||
|---|---|---|---|---|---|---|
Chimp | ELOVL fatty acid elongase 1 | |||||
Macaque | ELOVL fatty acid elongase 1 | |||||
Mouse | ||||||
Rat | ||||||
Dog | ELOVL fatty acid elongase 1 | |||||
Publication Statistics
PubMed Score 34.73
PubMed score by year
PubTator Score 36.68
PubTator score by year
Related Publications
Text Mined References (17)
GeneRif Annotations (5)
Items per page:
0 of 0
PMID | Year | Title |
|---|